Syntheses of two deacetyl-thymosin α1 analogues and their effects on low E-rosette-forming lymphocytes of uraemic patients

Two deacetyl-thymosin α1 analogues containing Phe (4Br) or D-Phe (4Br) residue—[D-Phe(4Br)21]deacetyl-thymosin α1 and [Phe(4Br)21]deacetyl-thymosin α1, respectively—were synthesized by the manual solid-phase method and their immunological effects on the low E-rosette-forming lymphocytes of uraemic patients were examined. One of the synthetic analogues, [Phe(4Br)21deacetyl-thymosin α1, demonstrated a restorative effect on the low E-rosette-forming lymphocytes of uraemic patients, which was stronger than that of deacetyl-thymosin α1, but the other analogue, [D-Phe(4Br)21]deacetyl-thymosin α1, showed no restorative effect under the same conditions

Functional roles of Phe12 of deacetyl-thymosin β4 in the impaired blastogenic response of uraemic T-lymphocytes

Phe12 of deacetyl-thymosin β4 is one of the structural essentials for restorative effect on the impaired blastogenic response of uraemic T-lymphocytes. In order to evaluate the functional roles of this phenyl group in the restorative effect on impaired T-lymphocytes, two analogues, [1- Nal12]deacetyl-thymosin β4 and [Cha12]deacetyl4 thymosin β4, were synthesized by a solid-phase method and evaluated for restorative effect on the impaired blastogenic response of uraemic T-lymphocytes. The results indicated that [1-Nal12]deacetyl-thymosin β4 which had a bulky naphthyl ring showed a stronger restorative effect than that of deacetyl-thymosin β4, but it was slightly weaker than that of [Phe(4F)12]deacetyl-thymosin β4. However, [Cha12]deacetyl-thymosin β4 showed no restorative effect on the impaired blastogenic response of uraemic T-lymphocytes

An Estimate of Vacancy Migration Energy from Aging Experiments in an Iron 3.8 at% Molybdenum Alloy(Physics)

Resistivity change during isochronal aging of a high purity Fe-3.8 at.% Mo alloy is investigated. The resistivity first decreases between 300℃ and 400℃, passing through a minimum it increases to a maximum at 650℃ and decreases again. Molybdenum atoms are considered to form clusters in the first stage of resistivity decrease. The clustering at temperatures below 400℃ is possible only when quenched-in excess vacancies are present and enhance the solute atom diffusion. This observation implies that vacancies in pure iron also migrate at an appreciable rate at around 350℃ with an activation energy of about 1.2 eV

The Use of XML to Express a Historical Knowledge Base

Non

Bio-implant as a novel restoration for tooth loss

published_or_final_versio

Current management strategies for the pain of elderly patients with burning mouth syndrome : a critical review

Burning Mouth Syndrome (BMS), a chronic intraoral burning sensation or dysesthesia without clinically evident causes, is one of the most common medically unexplained oral symptoms/syndromes. Even though the clinical features of BMS have been astonishingly common and consistent throughout the world for hundreds of years, BMS remains an enigma and has evolved to more intractable condition. In fact, there is a large and growing number of elderly BMS patients for whom the disease is accompanied by systemic diseases, in addition to aging physical change, which makes the diagnosis and treatment of BMS more difficult. Because the biggest barrier preventing us from finding the core pathophysiology and best therapy for BMS seems to be its heterogeneity, this syndrome remains challenging for clinicians. In this review, we discuss currently hopeful management strategies, including central neuromodulators (Tricyclic Antidepressants - TCAs, Serotonin, and Norepinephrine Reuptake Inhibitors - SNRIs, Selective Serotonin Reuptake Inhibitors - SSRIs, Clonazepam) and solutions for applying non-pharmacology approaches. Moreover, we also emphasize the important role of patient education and anxiety management to improve the patients’ quality of life. A combination of optimized medication with a short-term supportive psychotherapeutic approach might be a useful solution